Published on in Vol 22 , No 8 (2020) :August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/21778, first published .
Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Journals

  1. Edelman S, Cavaiola T, Boeder S, Pettus J. Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. Primary Care Diabetes 2021;15(2):199 View
  2. Galindo R, Parkin C, Aleppo G, Carlson A, Kruger D, Levy C, Umpierrez G, McGill J. What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2021;23(9):652 View
  3. Jackson M, Ahmann A, Shah V. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2021;23(S1):S-27 View
  4. Ang I, Tan K, Tan C, Tan C, Kwek J, Tay J, Toh S. A Personalized Mobile Health Program for Type 2 Diabetes During the COVID-19 Pandemic: Single-Group Pre–Post Study. JMIR Diabetes 2021;6(3):e25820 View
  5. Kruger D, Anderson J. Continuous Glucose Monitoring (CGM) Is a Tool, Not a Reward: Unjustified Insurance Coverage Criteria Limit Access to CGM. Diabetes Technology & Therapeutics 2021;23(S3):S-45 View
  6. Gavin J, Bailey C. Real-World Studies Support Use of Continuous Glucose Monitoring in Type 1 and Type 2 Diabetes Independently of Treatment Regimen. Diabetes Technology & Therapeutics 2021;23(S3):S-19 View
  7. Verma R, Bhardwaj S, Lathia T, Kalra S, Ranadive R, Tanna S, Padsalge M, Juneja A, Samundra K, Thakkar P, Jain V, Kini V, Kothari S, Guntur S, Joshi S, Singal A. Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days. International Journal of Diabetes in Developing Countries 2022 View
  8. Hirsch I, Miller E. Integrating Continuous Glucose Monitoring Into Clinical Practices and Patients' Lives. Diabetes Technology & Therapeutics 2021;23(S3):S-72 View
  9. Kompala T, Wong J, Neinstein A. Diabetes Specialists Value CGM Despite Challenges in Prescribing and Data Review Process. Journal of Diabetes Science and Technology 2022:193229682210882 View
  10. Vrany E, Hill-Briggs F, Ephraim P, Myers A, Garnica P, Fitzpatrick S. Continuous glucose monitors and virtual care in high-risk, racial and ethnic minority populations: Toward promoting health equity. Frontiers in Endocrinology 2023;14 View
  11. Chawla R, Jaggi S, Gupta A, Bantwal G, Patil S. Clinical Utility of a Digital Therapeutic Intervention in Indian Patients With Type 2 Diabetes Mellitus: 12-Week Prospective Single-Arm Intervention Study. JMIR Diabetes 2022;7(4):e41401 View
  12. Norman G, Paudel M, Parkin C, Bancroft T, Lynch P. Association Between Real-Time Continuous Glucose Monitor Use and Diabetes-Related Medical Costs for Patients with Type 2 Diabetes. Diabetes Technology & Therapeutics 2022;24(7):520 View
  13. Sharma V, Feldman M, Sharma R. Telehealth Technologies in Diabetes Self-management and Education. Journal of Diabetes Science and Technology 2022:193229682210930 View
  14. Joshi S, Verma R, Lathia T, Selvan C, Tanna S, Saraf A, Tiwaskar M, Modi A, Kalra S, Rao K, Chitale M, Malde F, Abdul Khader M, Singal A. Changes in HbA1c and weight in people with Type 2 Diabetes after continuous glucose monitoring based Diabefly-Pro digital therapeutics program: Analysis of real-world data (Preprint). JMIR Diabetes 2022 View
  15. Morris T, Aspinal F, Ledger J, Li K, Gomes M. The Impact of Digital Health Interventions for the Management of Type 2 Diabetes on Health and Social Care Utilisation and Costs: A Systematic Review. PharmacoEconomics - Open 2022 View
  16. Thomas A, Haak T, Tombek A, Kulzer B, Ehrmann D, Kordonouri O, Kroeger J, Schubert-Olesen O, Kolassa R, Siegmund T, Haller N, Heinemann L. Expertenaustausch zum Einsatz von kontinuierlichem Glukosemonitoring (CGM) im Diabetesmanagement: Eine aktuelle Bestandsaufnahme und Blick in die Zukunft. Diabetologie und Stoffwechsel 2023;18(01):57 View
  17. Schubert T, Clegg K, Karalis D, Desai N, Marrs J, McNeal C, Mintz G, Romagnoli K, Jones L. Impact of telehealth on the current and future practice of lipidology: a scoping review. Journal of Clinical Lipidology 2023;17(1):40 View
  18. Oser T, Litchman M, Allen N, Kwan B, Fisher L, Jortberg B, Polonsky W, Oser S. Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts. Current Diabetes Reports 2021;21(11) View
  19. Majithia A, Erani D, Kusiak C, Layne J, Lee A, Colangelo F, Romanelli R, Robertson S, Brown S, Dixon R, Zisser H. Medication Optimization Among People With Type 2 Diabetes Participating in a Continuous Glucose Monitoring–Driven Virtual Care Program: Prospective Study. JMIR Formative Research 2022;6(4):e31629 View
  20. Grace T, Salyer J. Use of Real-Time Continuous Glucose Monitoring Improves Glycemic Control and Other Clinical Outcomes in Type 2 Diabetes Patients Treated with Less Intensive Therapy. Diabetes Technology & Therapeutics 2022;24(1):26 View
  21. Cowart K, Updike W, Franks R. Continuous glucose monitoring in persons with type 2 diabetes not using insulin. Expert Review of Medical Devices 2021;18(11):1049 View
  22. Barnard-Kelly K, Parkin C. Health-care disparities in the use of diabetes technologies in the UK. International Journal of Diabetes and Technology 2023;0(0):0 View